Substance / Medication

Thiamazole

Overview

Active Ingredient
methimazole
RxNorm CUI
6835

Indications

Methimazole tablets are indicated: • In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option. • To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.

Labeler: Preferred Pharmaceuticals Inc.Updated: 2026-01-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Methimazole tablets are contraindicated in the presence of hypersensitivity to the drug or any of the other product components.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Thiamazole Pretreatment Lowers the (131)I Activity Needed to Cure Hyperthyroidism in Patients With Nodular Goiter.
Kyrilli Aglaia, Tang Bich-Ngoc-Thanh, Huyge Valérie et al. · J Clin Endocrinol Metab · 2015
PMID: 25867812RCT
Serum concentrations of methimazole in cats after a single oral dose of controlled-release carbimazole or sugar-coated methimazole (thiamazole).
Longhofer Susan L, Martín-Jiménez Tomás, Soni-Gupta Jyoti · Vet Ther · 2010
PMID: 20960416RCT
Drug-dependent antibodies against the prodrug carbimazole do not react with the metabolite thiamazole.
Kroll H, Giptner A, Santoso S · Blood · 2001
PMID: 11286225Observational
A case of thiamazole-induced erythema nodosum.
Hatano Yoko, Nakagawa Yukinobu, Tanemura Atsushi et al. · J Dermatol · 2023
PMID: 37222236Case Report
[Thiamazole-induced arthritis].
Brinkman Antonia, Schneider Udo, Buttgereit Frank et al. · Z Rheumatol · 2021
PMID: 33196862Case ReportFull text (PMC)
Thiamazole-Associated Neuropathy.
den Besten Milou, Engelen Marc, Sas Theo C J et al. · Thyroid · 2019
PMID: 30909818Case Report
Thiamazole-Induced Agranulocytosis Leading to Abscessus Pneumonia-Rare, But Challenging.
Lazovic Biljana, Andrejevic Vuk, Ivanovic Aleksandar et al. · Arch Bronconeumol (Engl Ed) · 2018
PMID: 29203051Case Report
Administration of thiamazole for Graves' disease might trigger the onset of type 1 diabetes.
Mizutani Gen, Hikima Yusuke, Satomura Atsushi et al. · J Diabetes Investig · 2018
PMID: 29900683Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Thiamazole (substance)
SNOMED CT
37656002
UMLS CUI
C0025644
RxNorm CUI
6835
Labeler
Preferred Pharmaceuticals Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.